Substantial evidence has indicated that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) could improve the partially attenuate left ventricular (LV) dilation and remodeling in HF, however, the morbidity and mortality of HF patients remain unacceptably high (Asgar et al., 2015; Zhang et al., 2020). The gene discussed is ACE; the disease is hydrops fetalis.